Nemapharm Inc.
This article was originally published in Start Up
Executive Summary
Drug Discovery Tools; Functional Genomics. NemaPharm is focused on nematode-based screening technologies for human drug discovery. NemaPharm scientists create nematode mutants defective for a gene homologous to a human disease-related gene. Mutants areare used as whole animal screens for a compound that corrects the defect caused by the mutation. Update: NemaPharm has since been acquired by Sequana Therapeutics Inc.